Esperion Reveals Pricing for Public Common Stock Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 07 2025
0mins
Should l Buy ?
Source: Globenewswire
Public Offering Announcement: Esperion Therapeutics has priced a public offering of 30 million shares of common stock at $2.50 per share, with expected gross proceeds of approximately $75 million, set to close around October 9, 2025.
Company Overview: Esperion focuses on developing oral, non-statin medications for patients with elevated LDL cholesterol and is advancing its pipeline, including next-generation ATP citrate lyase inhibitors, supported by a significant clinical trial.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
